96
Moderator Rachel Yalowich, Project Director, National Academy for State Health Policy

Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Moderator

Rachel Yalowich, Project Director, National Academy for State Health Policy

Page 2: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Logis.cs for the Webinar

•  Ifyouareunabletolistentothewebinarthroughyourcomputerspeakers,pleaseuseyourphone:Dialin:(866)519-2796AccessCode:725013

•  Lineswillnotbeopenduringthiswebinar.

•  Commentsareencouraged.PleaseusethatchatboxonthelowerleMcornerofyourscreen.

•  Thechatfeatureisavailable,butwillnotbevisibleinfullscreenmode

Page 3: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

DATA VISUALIZATION JENNIFER LYONS

[email protected]

Page 4: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Why is data viz so important?

Take Action Make Change

Communicate Need

Funding Illuminate Findings

Data Driven Decisions

Efficiency

Page 5: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 6: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 7: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

AccesstospacemustbeanaPonalpriority.

Page 8: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

VISUALIZATION PROCESS

Page 9: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

1.Buildit 2.Breakitdown 3.Emphasizeyourstory

VISUALIZATION PROCESS

Page 10: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

VISUALIZATION PROCESS

1.Buildit 2.Breakitdown 3.Emphasizeyourstory

Page 11: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

55%

45%

34%55%

45%

34%

34%

45%

55%

Page 12: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

55%

45%

34%55%

45%

34%

34%

45%

55%

CHART FUNK?

Page 13: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

CHOOSING THE RIGHT CHART

Page 14: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

100

80

75

8050

60

55

50

40

42

30 20

Jan Feb Mar April May June July Aug Sept Oct Nov Dec

Overthecourseoftheyear,salesdecreased.

Page 15: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

100

8075

80

50

6055

50

40 42

30

20

Jan Feb Mar April May June July Aug Sept Oct Nov Dec

Overthecourseoftheyear,salesdecreased.

Page 16: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

0% 10% 20% 30% 40% 50% 60% 70% 80% 90%

Maine

Wyoming

Arkansas

MassachuseZs

Alaska

Colorado

Montana

Idaho

NewYork

WestVirginia

Maryland

Delaware

Minnesota

Nevada

Texas

California

Virginia

Vermont

Louisiana

Illinois

Michigan

NorthCarolina

Georgia

NewJersey

Oregon

Florida

NewHampshire

Oklahoma

SouthDakota

Kansas

Utah

Kentucky

Missouri

Washington

Page 17: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 18: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 19: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

1.Buildit 2.Breakitdown 3.Emphasizeyourstory

VISUALIZATION PROCESS

Page 20: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

REDUCE CLUTTER

Page 21: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 22: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

0 50 100 150 200 250

Chicken

Beef

Fish

Tofu

Pork

Beans

ProteinPreference

ExtremelyDislike

Dislike

SlightlyDislike

Neutral

SlightlyLike

Like

ExtremelyLike

Page 23: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

30

45

60

115

120

210

20

20

50

20

10

10

215

200

155

130

135

45

Chicken

Beef

Fish

Beans

Pork

Tofu

OfallproteinopPons,mostpeopledisliketofu.

Dislike Neutral Like

Page 24: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

GESTALT

Page 25: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Proximity

Page 26: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 27: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 28: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

ExamplefromEvergreenData’sblog“DirectlyLabelinginExcel”

Page 29: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

ExamplefromEvergreenData’sblog“DirectlyLabelinginExcel”

Page 30: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

YES!

NO

ExamplefromStephanieEvergreenandJenniferLyonsresearchon“TheLinkBetweenGraphicDesignandActualReportUse”

Page 31: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

FocalPoint

Page 32: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

13

11

6

11 11

4

10

45

2

12

4

8

Jan. Feb. Mar. April May June July Aug. Sept. Oct. Nov. Dec.

There is an average in-flow of 8 veterans coming into our homeless system every month.

Page 33: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

13

11

6

11 11

4

10

45

2

12

4

8

Jan. Feb. Mar. April May June July Aug. Sept. Oct. Nov. Dec.

There is an average in-flow of 8 veterans coming into our homeless system every month.

Page 34: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

ConHnuity

Page 35: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

13

11

6

11 11

4

10

45

2

12

4

8

Jan. Feb. Mar. April May June July Aug. Sept. Oct. Nov. Dec.

There is an average in-flow of 8 veterans coming into our homeless system every month.

Page 36: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

13

11

6

11 11

4

10

45

2

12

4

8

Jan. Feb. Mar. April May June July Aug. Sept. Oct. Nov. Dec.

There is an average in-flow of 8 veterans coming into our homeless system every month.

Page 37: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

1.Buildit 2.Breakitdown 3.Emphasizeyourstory

VISUALIZATION PROCESS

Page 38: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

STRATEGIC TEXT

Page 39: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

ExamplefromAnnEmery’sBlog

Page 40: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

ExamplefromAnnEmery’sBlog

Page 41: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

DescripHveTitle AcHveTitle

Page 42: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

DescripHveTitle AcHveTitle

Protein Preferences

Page 43: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

DescripHveTitle AcHveTitle

Protein Preferences Of all protein options, most people dislike tofu.

Page 44: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

DescripHveTitle AcHveTitle

Protein Preferences Of all protein options, most people dislike tofu.

2015 vs. 2016 Program Enrollment by Race

Protein Preferences Of all protein options, most people dislike tofu.

Page 45: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

DescripHveTitle AcHveTitle

Protein Preferences Of all protein options, most people dislike tofu.

2015 vs. 2016 Program Enrollment by Race

2016 enrollment for people of color has increased by 5%.

Page 46: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

DescripHveTitle AcHveTitle

Protein Preferences Of all protein options, most people dislike tofu.

2015 vs. 2016 Program Enrollment by Race

2016 enrollment for people of color has increased by 5%.

Customer Satisfaction Survey Results

Page 47: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

DescripHveTitle AcHveTitle

Protein Preferences Of all protein options, most people dislike tofu.

2015 vs. 2016 Program Enrollment by Race

2016 enrollment for people of color has increased by 5%.

Customer Satisfaction Survey Results

Overall, respondents were most satisfied by our organization’s customer service and follow-up.

Page 48: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

COLOR

Page 49: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 50: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

I love learning about data visualization. It is so great to learn all of these new data best practices I will apply the things I have learned today to the data I use in my own work. Data visualization helps me better tell my story and communicate with my intended audience.

Page 51: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

I love learning about data visualization. It is so great to learn all of these new data best practices I will apply the things I have learned today to the data I use in my own work. Data visualization helps me better tell my story and communicate with my intended audience.

Page 52: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

2outof10peoplereceivingourservicesarewomen.

2outof10peoplereceivingourservicesarewomen.

VS.

Page 53: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

20%

30%

40%

50%

60%

70%

80%

Jan Feb Mar April May June July Aug Sept Oct Nov Dec

Region1 Region2 Region3 Region4 Region5

Regionalsalesfor2015

Page 54: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Jan Feb Mar April May June July Aug Sept Oct Nov Dec

Regionthreesustainedtheusualsummersalesslump.

80%

20%

70%

60%

50%

40%

30%

Region3

Region4

Region2

Region1

Region5

Page 55: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Jan Feb Mar April May June July Aug Sept Oct Nov Dec

Allsalesincreasedsignificantlyduringtheholidayseason.

80%

20%

70%

60%

50%

40%

30%

Region3

Region4

Region2

Region1

Region5

Page 56: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

COLOR

ExamplefromEvergreenData’sBlog

Page 57: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 58: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

SOCIAL MEDIA

Page 59: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

PRESS

Page 60: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 61: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 62: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 63: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 64: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 65: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

DASHBOARD

ExamplefromNatalyaWawrin’sworkwiththeVAinAnnArbor

Page 66: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive
Page 67: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

DATA VISUALIZATION JENNIFER LYONS

[email protected]

Page 68: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

MA DEPARTMENT OF PUBLIC HEALTH Monica Bharel, MD MPH Commissioner of Public Health

Page 69: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

HIV/AIDS IN MASSACHUSETTS

July 2017

Page 70: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

People Diagnosed with HIV Infection by Exposure Mode 2013 - 2015

by Exposure Mode: Massachusetts, 2013–2015

N=1,994 Undetermined

28%

Heterosexual Sex6%

Injection Drug Use6%

MSM/IDU2%

Other1%

Presumed Heterosexual Sex (Females)

13%

Male-to-Male Sex44%

Data Source: MDPH HIV/AIDS Surveillance Program, Data as of 1/1/17

Page 71: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Individuals Diagnosed with HIV Infection by Exposure Mode and Year of Diagnosis: Massachusetts, 2005–2015

0

50

100

150

200

250

300

350

400

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015Year of Diagnosis

HIV

Dia

gnos

es

IDU Pres. HTSX HTSX

Data Source: MDPH HIV/AIDS Surveillance Program; Data as of 1/1/17

MSM

MSM/IDU

NIR

Other

Page 72: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Percentage Distribution of Deaths among People Reported with HIV/AIDS: Selected Exposure Modes & Year of Death: 2005–2014

0%

10%

20%

30%

40%

50%

60%

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

Percent

Year of Diagnosis

N=2,732; HTSX = Heterosexual Sex; Pres. HTSX = Presumed Heterosexual Sex Data Source: MDPH HIV/AIDS Surveillance Program; Data are current as of 3/1/16 and may be subject to change

PRES. HTSX

Undetermined

Injection Drug Use

Male-to-Male Sex

HTSX

Page 73: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Proportion of Individuals Diagnosed with HIV Infection Among PWID by Race and Year of Diagnosis:

Massachusetts, 2012–2015

Data Source: MDPH HIV/AIDS Surveillance Program; Data as of 1/1/17

Page 74: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

OPIOIDS: USING DATA TO UNCOVER TRUTHS AND GUIDE POLICY July 2017

Page 75: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Opioid Related Deaths

379506 526

614514 575

660 642 622 638 560656

742

961

1,361

1,6511,933

1,793

2,069

0200400600800

1,0001,2001,4001,6001,8002,0002,200

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

Num

berofd

eaths

Figure1.Opioid1-RelatedDeaths,AllIntentsMassachusettsResidents:January2000- December2016

Confirmed Estimated

70% OF OPIOID DEATHS IN 2016 HAD THE PRESENCE OF FENTANYL

446% INCREASE IN 16 YEARS

Page 76: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Opioid Related Deaths

0

10

20

30

40

50

60

70

80

90

1 2 3 4 1 2 3 4 1 2 3 4

2014 2015 2016

Percen

t

YearandQuarter

Figure4.PercentofOpioidDeathswithSpecificDrugsPresentMA:2014-2016

Fentanyl¹

LikelyHeroin

PrescriptionOpioid²

Benzodiazepine

Cocaine

Page 77: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Opioid Related Deaths

Page 78: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Opioid Overdose Death Rates, All Intents Massachusetts: 2011-2013 vs. 2014 - 2016

Page 79: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Prevention Intervention Treatment Recovery

Governor Baker’s Opioid Working Group

Page 80: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Massachusetts Chapter 55 Legislation • Signed into law in August 2015

• Requires a comprehensive report to the state legislature and cross-agency collaboration to address 7 specific questions about opioid-related deaths

• Specifies major data sets across government

• Overcomes legal barriers for use of some data

• Work highlighted by Public Health Accreditation Board on their site visit

Page 81: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Chapter 55 Data Mapping

PDMP

APCDSpine

DeathRecords

BSASTreatment

Toxicology

MedicalClaims

MATRIS(EMS)

OCMEIntake

HospitalandED

MAPrisons

MAJails

MassHealth

DMH DHCD

StatePoliceOpioid

BirthRecords

Veterans’Services

TransiHonalAssistance

YouthServices

Children&Families

ServiceIndicatorFlagsCancerRegistry

DeptDevServices

CommissionforBlind

Chapter55DataStructure

NeedleExchange

NARCANDistribuHon

DrugSeizureData

Town&ZipCensusData

CommunityLevelData

MDPHnetDepression

I.C.E.Measures

Page 82: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

PSI#1&#2

PSI#1APCDSPINEPSI#1

PSI#1&#3

PSI#1&#4

PSI#1&#5

PSI#1&#N

PSI = Project Specific Identifier

Enterprise SAS or other software (Fixed or Cloud-based servers)

Machine 1

Machine 2

Machine 5 Machine

4 Machine

3

Machine 6

Machine 7

Machine N

Machine 8

…addiHonaldata…

…addiHonalmachines…

…addiHonaldata…

Chapter 55 Privacy Shield: Authorized users only, no write access, analysts cannot see data, automatic cell suppression, delete all temporary work files, full auditability of all data operations.

DRAFT - FOR POLICY DEVELOPMENT ONLY

PSI#2&AnalyPc

PSI#3&AnalyPc

PSI#4&AnalyPc

PSI#5&AnalyPc

PSI#N&AnalyPc

Chapter55:SecureDataAccess

Page 83: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Chapter55:PartnersComingTogetherAcademic

• BrandeisUniversity• BostonUniversity• BrownUniversity• HarvardMedicalSchool• HarvardSchoolofPublicHealth• MassachuseasCollegeofPharmacyandHealthSciences• MassachuseasInsHtuteofTechnology• NortheasternUniversity• TubsUniversity• UniversityofMassachuseasAmherst• UniversityofMassachuseasBoston• UniversityofMassachuseasMedicalSchool

StateandFederalGovernmentAgencies

Hospitals&PrivateIndustry

• BaystateHealth• BethIsraelDeaconessMedicalCenter• BostonMedicalCenter• Brigham&Women’sHospital• Children’sHospital• GE• IBM• LibertyMutual• MassachuseasGeneralHospital• MassachuseasLeagueofCommunityHealthCenters• McKinsey&Company• TheMITRECorporaHon• PartnersHealthcare• PwC• RandCorporaHon

•  BostonPublicHealthCommission•  CenterforHealthInformaHonandAnalysis•  DepartmentofHousingandCommunityDevelopment•  DepartmentofMentalHealth•  DepartmentofCorrecHon•  DepartmentofPublicHealth•  ExecuHveOfficeofHealthandHumanServices•  ExecuHveOfficeofPublicSafetyandSecurity

•  FederalBureauofInvesHgaHon•  HighIntensityDrugTraffickingArea(NE)•  HealthPolicyCommission•  MassachuseasSheriffs’AssociaHon•  MassIT•  OfficeoftheChiefMedicalExaminer•  StateAuditor’sOffice

Page 84: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Data Mapping: Key finding

•  Patients treated with methadone and/or buprenorphine (Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die.

•  Very few patients (~5%) receive Opioid Agonist Treatment following a non-fatal overdose.

0

0.5

1

1.5

2

2.5

Engaged in OAT Not Engaged in OAT

Cum

ulat

ive

Inci

denc

e (%

)

Cumulative Incidence of Opioid-Related Death by Opioid Agonist Treatment Status

Page 85: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Data Mapping: Key finding The risk of opioid overdose death following incarceration is 56 times higher than for the general public.

869.4 opioid deaths / 100,000

15.4 opioid deaths/ 100,000

0

100

200

300

400

500

600

700

800

900

1000

Former Inmates All Others

Comparison of Opioid Death Rates Among Former Inmates to the Rest of State (2013 - 2014)

Page 86: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Does an abnormally high amount of

prescribing physicians increase a

patient’s risk of fatal overdose?

Individuals who obtain opioid prescriptions from

more than 1 doctor may be at greater risk of death.

Based on observed data, the use of 3 or more prescribers

is associated with a 7-fold increase in risk of fatal

opioid overdose.

Does the addition of benzodiazepines to opioids increase

the risk of fatal opioid overdose

relative to taking opioids alone?

Preliminary findings support the hypothesis of increased risk of fatal overdose associated with concurrent use of opioids and

benzodiazepines.

Based on observed data, the use of benzodiazepines concurrent to opioids is associated with a 4-fold

increase in risk of fatal opioid overdose.

ANALYTIC QUESTION PRELIMINARY FINDING

Datamapping–KeyFindings

Page 87: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

PMP activity trends

Page 88: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

14.3 13.6

10.6

7.7

4.0

8.0

12.0

16.0

2013 2014 2015 2016

Rateper1,000In

dividu

als

Figure3.Rate1 ofIndividualswithActivityofConcern2 inMA3

2013–2016

ActivityofConcern

1 Ratesofindividualswithactivityofconcernarebasedonthepopulationofindividuals whohavereceivedoneormoreSchedule IIopioidprescriptions.2 "ActivityofConcern"isdefinedasanindividual whoreceivedprescriptions foroneormoreScheduleIIopioiddrugsfromfourormoredifferentprescribersandhadthemfilledatfourormorepharmaciesduring thespecifiedtimeperiod.3 ActivityofconcernratesincludeonlyMAResidents

PMP activity trends

Page 89: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

6.0

7.9

8.2

9.6

8.08.9

10.3 10.0

9.6

9.7

8.010.0

11.2 14.4

20.2

26.4

30.5

0

5

10

15

20

25

30

35

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

Rate

per1

00,000

Residen

ts

Figure3.RateofOpioid1-RelatedDeaths,AllIntentsMassachusettsResidents:2000-2016

Opioid Related Deaths

40%

31%

16%

Page 90: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Data visualization of findings from Chapter 55 Report

Monica Bharel, MD, MPH Commissioner, Massachusetts Department of Public Health

http://www.mass.gov/chapter55/

Page 91: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Opioid map – Chapter 55 Visualization

Chapter 55 website allows for town-by-town analysis

Page 92: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Chapter 55 Visualization

Adding interactive elements to help localize the epidemic

Page 93: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Connecting data with a story…

Page 94: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

THANK YOU & QUESTIONS

Page 95: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

Ques.ons

Page 96: Rachel Yalowich Project Director, National …...(Opioid Agonist Treatment) following a non-fatal overdose were significantly less likely to die. • Very few patients (~5%) receive

HIVHealthImprovementAffinityGroup

ThankyouforparPcipaPngintoday’swebinar!PleasecompletetheevaluaPonaMerexiPngthewebinar.